Meeting report: 34th international conference on antiviral research - Interactions entre HBV, HDV, et des facteurs hépatiques de l'hôte
Article Dans Une Revue Antiviral Chemistry and Chemotherapy Année : 2022

Meeting report: 34th international conference on antiviral research

Richard J Whitley
  • Fonction : Auteur
Jessica R Spengler

Résumé

As a result of the multiple gathering and travels restrictions during the SARS-CoV-2 pandemic, the annual meeting of the International Society for Antiviral Research (ISAR), the International Conference on Antiviral Research (ICAR), could not be held in person in 2021. Nonetheless, ISAR successfully organized a remote conference, retaining the most critical aspects of all ICARs, a collegiate gathering of researchers in academia, industry, government and non-governmental institutions working to develop, identify, and evaluate effective antiviral therapy for the benefit of all human beings. This article highlights the 2021 remote meeting, which presented the advances and objectives of antiviral and vaccine discovery, research, and development. The meeting resulted in a dynamic and effective exchange of ideas and information, positively impacting the prompt progress towards new and effective prophylaxis and therapeutics.
Fichier principal
Vignette du fichier
brancale-et-al-2022-meeting-report-34th-international-conference-on-antiviral-research.pdf (995.3 Ko) Télécharger le fichier
Origine Fichiers éditeurs autorisés sur une archive ouverte

Dates et versions

hal-04121353 , version 1 (07-06-2023)

Identifiants

Citer

Andrea Brancale, Kara Carter, Leen Delang, Jerome Deval, David Durantel, et al.. Meeting report: 34th international conference on antiviral research. Antiviral Chemistry and Chemotherapy, 2022, 30, pp.204020662211308. ⟨10.1177/20402066221130853⟩. ⟨hal-04121353⟩
40 Consultations
39 Téléchargements

Altmetric

Partager

More